Denali Therapeutics' (DNLI) Outperform Rating Reaffirmed at William Blair

William Blair reiterated their outperform rating on shares of Denali Therapeutics (NASDAQ:DNLI - Free Report) in a report published on Wednesday,RTT News reports.

Several other equities analysts have also recently commented on the stock. Jefferies Financial Group raised their target price on shares of Denali Therapeutics from $40.00 to $45.00 and gave the company a "buy" rating in a research note on Friday, November 1st. Stifel Nicolaus upgraded shares of Denali Therapeutics from a "hold" rating to a "buy" rating and set a $37.00 price objective on the stock in a research note on Monday, December 16th. Cantor Fitzgerald downgraded Denali Therapeutics from an "overweight" rating to a "neutral" rating in a research report on Monday, October 7th. Robert W. Baird initiated coverage on Denali Therapeutics in a research note on Tuesday, January 7th. They set an "outperform" rating and a $31.00 price target for the company. Finally, HC Wainwright dropped their price objective on Denali Therapeutics from $90.00 to $87.00 and set a "buy" rating on the stock in a research note on Tuesday, January 7th. Two investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Denali Therapeutics currently has an average rating of "Moderate Buy" and a consensus price target of $38.91.

Denali Therapeutics Price Performance

DNLI stock traded up $2.76 on Wednesday, reaching $21.50. The company's stock had a trading volume of 1,693,340 shares, compared to its average volume of 1,187,771. Denali Therapeutics has a 52 week low of $14.56 and a 52 week high of $33.33. The company has a market capitalization of $3.09 billion, a P/E ratio of -7.79 and a beta of 1.39. The firm has a fifty day moving average of $23.48 and a two-hundred day moving average of $24.77.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.03). During the same period in the prior year, the company earned ($0.72) earnings per share. As a group, equities analysts expect that Denali Therapeutics will post -2.71 EPS for the current fiscal year.

Insider Transactions at Denali Therapeutics

In other Denali Therapeutics news, Director Vicki L. Sato sold 1,020 shares of the firm's stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $30.00, for a total value of $30,600.00. Following the completion of the transaction, the director now directly owns 111,056 shares in the company, valued at $3,331,680. This trade represents a 0.91 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Ryan J. Watts sold 40,000 shares of the business's stock in a transaction that occurred on Friday, October 18th. The shares were sold at an average price of $27.69, for a total transaction of $1,107,600.00. Following the sale, the chief executive officer now owns 235,807 shares in the company, valued at $6,529,495.83. This represents a 14.50 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 104,518 shares of company stock valued at $2,576,982 over the last three months. Company insiders own 7.90% of the company's stock.

Hedge Funds Weigh In On Denali Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Victory Capital Management Inc. lifted its holdings in shares of Denali Therapeutics by 163.7% in the third quarter. Victory Capital Management Inc. now owns 39,900 shares of the company's stock valued at $1,162,000 after purchasing an additional 24,767 shares in the last quarter. FMR LLC raised its position in Denali Therapeutics by 3,234.3% during the third quarter. FMR LLC now owns 7,831,378 shares of the company's stock valued at $228,128,000 after buying an additional 7,596,508 shares during the period. Algert Global LLC lifted its stake in Denali Therapeutics by 82.4% in the 3rd quarter. Algert Global LLC now owns 48,630 shares of the company's stock worth $1,417,000 after acquiring an additional 21,975 shares in the last quarter. Integral Health Asset Management LLC acquired a new stake in Denali Therapeutics during the 2nd quarter worth about $7,546,000. Finally, Principal Financial Group Inc. grew its stake in Denali Therapeutics by 13.8% during the 3rd quarter. Principal Financial Group Inc. now owns 1,238,476 shares of the company's stock valued at $36,076,000 after acquiring an additional 149,939 shares in the last quarter. Institutional investors and hedge funds own 92.92% of the company's stock.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.